Latest Headlines

Latest Headlines

Regulators in Europe propose bans on plants in China and India

According to reports posted on the EudraGMDP site, regulators from Italy recommended bans on specific products made by Jinan Jinda Pharmaceutical in Shandong Province in China and Wuxi Jida Pharmaceutical in Jiangsu City, China, as well as Parabolic Drugs in Haryana, India.

Hikma gets large U.S. plant in Boehringer Ingelheim generics deal

Last year when Hikma bought Boehringer Ingelheim's Ben Venue injectable business, it decided not to reopen its long-troubled Bedford, OH, plant. But with a $2.65 billion deal announced today for Boehringer's Roxane generics business, it gets a U.S. manufacturing plant that it says it likes the looks of.

Sun may only get 3 of Ranbaxy's 4 banned plants ready for U.S. market

Ranbaxy Laboratories, which Sun Pharmaceutical recently acquired for $4 billion, has four plants in India that once produced products for the U.S. market. All four were banned by the FDA over the last 5 years for manufacturing and drug testing issues. But Sun may now only intend to spend the time and money to get three of them back to FDA standards.

Capsugel expanding plant in Scotland

Capsule maker and drug formulation specialist Capsugel has been beefing up its production capacities around the globe and will now turn its attention to a plant in Scotland that it picked up in 2013.

Patheon, DPx unload chemical operations to tighten focus on pharma

Patheon and its parent, DPx, have been on a buying and expansion binge since the company was created last year, grabbing up smaller CMOs to build out both capabilities and capacity. With an IPO in the works, more deals may be coming but the CDMO has ended up with operations that don't fit its model and is shedding those along the way, including two deals this week.

Sandoz gives Novartis a boost, but 3 plants still get the boot

Novartis's generics business Sandoz provided the key bright spot in an otherwise tough earnings report for the Swiss pharma, with revenues up 10%. But the starring performance did not keep the manufacturing side of Sandoz from getting spanked, with three of its plants now targeted for closing.

Amgen's Colorado plant hits the market for $85M

Amgen's manufacturing and R&D sites in Colorado are officially on the block and the company is hoping another drugmaker will be interested in buying them.

Biogen gets all of North Carolina site from Eisai as part of manufacturing build-out

When Biogen announced a few weeks ago that it intends to build a $1 billion new biologics plant in Switzerland, officials said the Cambridge, MA-based company had more manufacturing expansion up its sleeve. At least part of the great reveal was made last week when Japanese partner Eisai said it was turning over manufacturing operations in North Carolina to Biogen.

J&J expects Fort Washington, PA, consumer plant to be back on line soon

Two Johnson & Johnson consumer health plants that operate under a consent decree from the FDA will no longer need to be monitored by outsiders, and the plant that was ground zero for the company's consumer health quagmire is expected to go back online after being sidelined for 5 years to regain standing with the FDA.

Pfizer announces it will shutter India plant, echoing same news from Sandoz

Pfizer will be closing a plant in India later this year. The announcement comes less than a week after Novartis announced that its Sandoz generics unit would close a plant in India at the end of 2016.